Moderna, Inc. (0A45.L)
| Previous close | 165.20 |
| Open | 167.14 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 165.36 - 170.31 |
| 52-week range | 95.06 - 217.15 |
| Volume | |
| Avg. volume | 12,058 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | 0.05 |
| EPS (TTM) | 34.02 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness
In the last year, many Moderna, Inc. ( NASDAQ:MRNA ) insiders sold a substantial stake in the company which may have...
- Simply Wall St.
Investing in Moderna (NASDAQ:MRNA) five years ago would have delivered you a 367% gain
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...
- Yahoo Finance Video
Moderna stock jumps on positive data for cancer vaccine
Shares of Moderna (MRNA) are moving up on Tuesday afternoon after the company released positive data for its individualized cancer vaccine tested in combination with Merck's Keytruda (MRK). The vaccine aims to train patients' immune systems to recognize and attack specific mutations in cancer cells. Yahoo Finance Anchors Josh Lipton and Julie Hyman break down Moderna's recent trial data. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's note: This article was written by Nicholas Jacobino
